Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Taipei Exchange - Delayed Quote TWD

Genovate Biotechnology Co., Ltd. (4130.TWO)

Compare
21.60
+0.05
+(0.23%)
At close: April 2 at 1:30:36 PM GMT+8
Loading Chart for 4130.TWO
  • Previous Close 21.55
  • Open 21.70
  • Bid --
  • Ask --
  • Day's Range 21.55 - 21.70
  • 52 Week Range 20.39 - 26.40
  • Volume 21,127
  • Avg. Volume 395,762
  • Market Cap (intraday) 2.409B
  • Beta (5Y Monthly) 0.18
  • PE Ratio (TTM) 93.91
  • EPS (TTM) 0.23
  • Earnings Date --
  • Forward Dividend & Yield 0.15 (0.65%)
  • Ex-Dividend Date Aug 21, 2024
  • 1y Target Est --

Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. The company was founded in 1982 and is based in Hsinchu City, Taiwan.

www.genovate-bio.com

197

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4130.TWO

View More

Performance Overview: 4130.TWO

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4130.TWO
3.85%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
7.54%

1-Year Return

4130.TWO
10.77%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
4.06%

3-Year Return

4130.TWO
7.72%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
20.84%

5-Year Return

4130.TWO
17.37%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
120.40%

Compare To: 4130.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4130.TWO

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    2.41B

  • Enterprise Value

    1.89B

  • Trailing P/E

    93.91

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.72

  • Price/Book (mrq)

    1.66

  • Enterprise Value/Revenue

    3.70

  • Enterprise Value/EBITDA

    27.23

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.10%

  • Return on Assets (ttm)

    0.59%

  • Return on Equity (ttm)

    1.08%

  • Revenue (ttm)

    512.08M

  • Net Income Avi to Common (ttm)

    15.87M

  • Diluted EPS (ttm)

    0.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    525.69M

  • Total Debt/Equity (mrq)

    0.19%

  • Levered Free Cash Flow (ttm)

    26.72M

Research Analysis: 4130.TWO

View More

Company Insights: 4130.TWO

Research Reports: 4130.TWO

View More

People Also Watch